Barclays raised the firm’s price target on Protagonist Therapeutics (PTGX) to $108 from $88 and keeps an Overweight rating on the shares. The firm adjusted price targets in the biotechnology space as part of its 2026 outlook.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTGX:
- Promising Clinical Data and Strategic Collaborations Drive Buy Rating for Protagonist Therapeutics
- Protagonist Therapeutics price target raised to $115 from $98 at Citi
- Protagonist, Takeda present longer-term data at ASH 2025 on rusfertide
- Protagonist Therapeutics price target raised to $65 from $47 at Goldman Sachs
- Protagonist Therapeutics price target raised to $98 from $96 at Citi